Alshehri Sultan, Alshammari Rehab, Alyamani Mohammad, Dabbagh Rufaidah, Almalki Bander, Aldosari Omamah, Alsowayigh Renad, Alkudeer Amirah, Aldosari Fatimah, Sabr Jumana, Shakeel Faiyaz
Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia.
Department of Pharmaceutical Sciences, College of Pharmacy, AlMaarefa University, Ad Diriyah 13713, Saudi Arabia.
Saudi Pharm J. 2023 Apr;31(4):605-616. doi: 10.1016/j.jsps.2023.03.001. Epub 2023 Mar 8.
This observational descriptive study that was carried out with the objective of exploring the contribution of the local pharmaceutical industry to the Saudi drug security. Using a drug formulary provided from the Saudi Food and Drug Authority, containing all registered pharmaceutical products available in Saudi Arabia, we extracted information about drug class, drug type, country and place of manufacturing, shelf-life and price. Results showed that the majority of drugs in the market are manufactured in Europe (43.86%), followed by Saudi Arabia (22.55%), China and India (20.47%), Americas (10.24%), and other nations (2.61%). Most of the manufactured drugs were prescription drugs (90.62%). In this work, the local pharmaceutical industry with the highest percentage of contribution to local drug security was Pharmaceutical Solution Industries (PSI), representing the 5% of the items available in the Saudi market. The second highest percentage was 4% by TABUK Pharmaceutical Manufacturing CO., followed by SPIMACO (3%), JAMJOOM pharmaceutical company (2%), Riyadh pharma (2%), and Jazeera pharmaceutical industries (2%). In addition, results from this study provide information about the most essential pharmaceutical products that needs to be nationally manufactured or increased in production in order to rise the contribution of local pharmaceutical industries in Saudi drug security. Unfortunately, the small contribution of the Saudi pharmaceutical industry in local drug security increases the burden on the Kingdom's annual budget due to the over-reliance on international pharmaceuticals.
这项观察性描述性研究旨在探索当地制药行业对沙特药品安全的贡献。我们使用沙特食品药品管理局提供的药品处方集，其中包含沙特阿拉伯所有注册的药品，提取了有关药品类别、剂型、生产国家和地点、保质期和价格的信息。结果显示，市场上大多数药品在欧洲生产（43.86%），其次是沙特阿拉伯（22.55%）、中国和印度（20.47%）、美洲（10.24%）以及其他国家（2.61%）。大多数生产的药品为处方药（90.62%）。在这项研究中，对当地药品安全贡献比例最高的当地制药企业是制药解决方案工业公司（PSI），占沙特市场上在售药品的5%。贡献比例第二高的是塔布克制药制造公司，为4%，其次是SPIMACO（3%）、Jamjoom制药公司（2%）、利雅得制药公司（2%）和半岛制药工业公司（2%）。此外，这项研究的结果提供了有关最基本药品的信息，这些药品需要在国内生产或增加产量，以提高当地制药行业在沙特药品安全方面的贡献。不幸的是，沙特制药行业在当地药品安全方面的贡献较小，由于过度依赖国际药品，增加了沙特王国年度预算的负担。
